Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AMPA-type glutamate receptors are tetrameric ligand-gated ion channels predominantly mediating fast excitatory neurotransmission in the central nervous system. Each receptor is formed by different combinations of the GluA1–GluA4 (GluR1–GluR4) subunits. The presence or absence of the GluA2 subunit dictates functional properties, most critically the receptor’s permeability to calcium ions (Ca2+). GluA2-lacking AMPA receptors—composed of GluA1, GluA3, and/or GluA4 subunits—are permeable to Ca2+, exhibit inward rectification, and play crucial roles in synaptic plasticity, but are also associated with increased neuronal vulnerability to excitotoxicity. GluA2-lacking AMPA receptors are key functional subtypes implicated in neurological diseases and represent important therapeutic targets[1][3][5].
Competitive antagonism at the glutamate binding site - Non-competitive (allosteric) antagonism at sites distinct from the agonist - Block of calcium-permeable ion flux through AMPAR channel
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AMPA-type glutamate receptor (GluA2-lacking).